nodes	percent_of_prediction	percent_of_DWPC	metapath
Lercanidipine—CYP3A5—Teniposide—lymphatic system cancer	0.154	0.249	CbGbCtD
Lercanidipine—CYP3A7—Vincristine—lymphatic system cancer	0.0985	0.16	CbGbCtD
Lercanidipine—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0985	0.16	CbGbCtD
Lercanidipine—CYP3A5—Vincristine—lymphatic system cancer	0.0739	0.12	CbGbCtD
Lercanidipine—CYP3A4—Cytarabine—lymphatic system cancer	0.0608	0.0987	CbGbCtD
Lercanidipine—CYP3A4—Teniposide—lymphatic system cancer	0.0599	0.0972	CbGbCtD
Lercanidipine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0419	0.068	CbGbCtD
Lercanidipine—CYP3A4—Vincristine—lymphatic system cancer	0.0288	0.0468	CbGbCtD
Lercanidipine—Dyspnoea—Fludarabine—lymphatic system cancer	0.000876	0.00228	CcSEcCtD
Lercanidipine—Oedema peripheral—Carmustine—lymphatic system cancer	0.000872	0.00227	CcSEcCtD
Lercanidipine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00087	0.00227	CcSEcCtD
Lercanidipine—Dyspepsia—Fludarabine—lymphatic system cancer	0.000865	0.00225	CcSEcCtD
Lercanidipine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000856	0.00223	CcSEcCtD
Lercanidipine—Decreased appetite—Fludarabine—lymphatic system cancer	0.000854	0.00222	CcSEcCtD
Lercanidipine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000849	0.00221	CcSEcCtD
Lercanidipine—Fatigue—Fludarabine—lymphatic system cancer	0.000847	0.00221	CcSEcCtD
Lercanidipine—Constipation—Fludarabine—lymphatic system cancer	0.000841	0.00219	CcSEcCtD
Lercanidipine—Vasculitis—Methotrexate—lymphatic system cancer	0.000837	0.00218	CcSEcCtD
Lercanidipine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000835	0.00217	CcSEcCtD
Lercanidipine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000831	0.00216	CcSEcCtD
Lercanidipine—Urethral disorder—Vincristine—lymphatic system cancer	0.000829	0.00216	CcSEcCtD
Lercanidipine—Eye disorder—Carmustine—lymphatic system cancer	0.000828	0.00215	CcSEcCtD
Lercanidipine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000825	0.00215	CcSEcCtD
Lercanidipine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000824	0.00214	CcSEcCtD
Lercanidipine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000823	0.00214	CcSEcCtD
Lercanidipine—Flushing—Carmustine—lymphatic system cancer	0.000822	0.00214	CcSEcCtD
Lercanidipine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000819	0.00213	CcSEcCtD
Lercanidipine—Anaemia—Bleomycin—lymphatic system cancer	0.000816	0.00212	CcSEcCtD
Lercanidipine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00081	0.00211	CcSEcCtD
Lercanidipine—Asthenia—Teniposide—lymphatic system cancer	0.000802	0.00209	CcSEcCtD
Lercanidipine—Malaise—Bleomycin—lymphatic system cancer	0.000796	0.00207	CcSEcCtD
Lercanidipine—Pruritus—Teniposide—lymphatic system cancer	0.000791	0.00206	CcSEcCtD
Lercanidipine—Cardiac disorder—Vincristine—lymphatic system cancer	0.000785	0.00204	CcSEcCtD
Lercanidipine—Alopecia—Carmustine—lymphatic system cancer	0.000782	0.00204	CcSEcCtD
Lercanidipine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000777	0.00202	CcSEcCtD
Lercanidipine—Mental disorder—Carmustine—lymphatic system cancer	0.000776	0.00202	CcSEcCtD
Lercanidipine—Erythema—Carmustine—lymphatic system cancer	0.000771	0.00201	CcSEcCtD
Lercanidipine—Malnutrition—Carmustine—lymphatic system cancer	0.000771	0.00201	CcSEcCtD
Lercanidipine—Cough—Bleomycin—lymphatic system cancer	0.000771	0.00201	CcSEcCtD
Lercanidipine—Angiopathy—Vincristine—lymphatic system cancer	0.000767	0.002	CcSEcCtD
Lercanidipine—Diarrhoea—Teniposide—lymphatic system cancer	0.000765	0.00199	CcSEcCtD
Lercanidipine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000762	0.00198	CcSEcCtD
Lercanidipine—Chest pain—Bleomycin—lymphatic system cancer	0.000752	0.00196	CcSEcCtD
Lercanidipine—Myalgia—Bleomycin—lymphatic system cancer	0.000752	0.00196	CcSEcCtD
Lercanidipine—Alopecia—Vincristine—lymphatic system cancer	0.000747	0.00194	CcSEcCtD
Lercanidipine—Discomfort—Bleomycin—lymphatic system cancer	0.000743	0.00193	CcSEcCtD
Lercanidipine—Mental disorder—Vincristine—lymphatic system cancer	0.000741	0.00193	CcSEcCtD
Lercanidipine—Urine output increased—Methotrexate—lymphatic system cancer	0.000738	0.00192	CcSEcCtD
Lercanidipine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000731	0.0019	CcSEcCtD
Lercanidipine—Alopecia—Mitoxantrone—lymphatic system cancer	0.000727	0.00189	CcSEcCtD
Lercanidipine—Confusional state—Bleomycin—lymphatic system cancer	0.000727	0.00189	CcSEcCtD
Lercanidipine—Vision blurred—Carmustine—lymphatic system cancer	0.000726	0.00189	CcSEcCtD
Lercanidipine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000724	0.00189	CcSEcCtD
Lercanidipine—Erythema—Mitoxantrone—lymphatic system cancer	0.000717	0.00187	CcSEcCtD
Lercanidipine—Anaemia—Carmustine—lymphatic system cancer	0.000712	0.00185	CcSEcCtD
Lercanidipine—Vomiting—Teniposide—lymphatic system cancer	0.000711	0.00185	CcSEcCtD
Lercanidipine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000706	0.00184	CcSEcCtD
Lercanidipine—Asthenia—Fludarabine—lymphatic system cancer	0.000705	0.00184	CcSEcCtD
Lercanidipine—Rash—Teniposide—lymphatic system cancer	0.000705	0.00184	CcSEcCtD
Lercanidipine—Dermatitis—Teniposide—lymphatic system cancer	0.000705	0.00183	CcSEcCtD
Lercanidipine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000702	0.00183	CcSEcCtD
Lercanidipine—Headache—Teniposide—lymphatic system cancer	0.000701	0.00182	CcSEcCtD
Lercanidipine—Pruritus—Fludarabine—lymphatic system cancer	0.000695	0.00181	CcSEcCtD
Lercanidipine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000695	0.00181	CcSEcCtD
Lercanidipine—Anorexia—Bleomycin—lymphatic system cancer	0.000687	0.00179	CcSEcCtD
Lercanidipine—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000682	0.00177	CcSEcCtD
Lercanidipine—Anaemia—Vincristine—lymphatic system cancer	0.00068	0.00177	CcSEcCtD
Lercanidipine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000675	0.00176	CcSEcCtD
Lercanidipine—Polyuria—Methotrexate—lymphatic system cancer	0.000675	0.00176	CcSEcCtD
Lercanidipine—Photosensitivity—Methotrexate—lymphatic system cancer	0.000675	0.00176	CcSEcCtD
Lercanidipine—Hypotension—Bleomycin—lymphatic system cancer	0.000673	0.00175	CcSEcCtD
Lercanidipine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000673	0.00175	CcSEcCtD
Lercanidipine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000665	0.00173	CcSEcCtD
Lercanidipine—Nausea—Teniposide—lymphatic system cancer	0.000664	0.00173	CcSEcCtD
Lercanidipine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000662	0.00172	CcSEcCtD
Lercanidipine—Vertigo—Vincristine—lymphatic system cancer	0.000661	0.00172	CcSEcCtD
Lercanidipine—Hepatic failure—Methotrexate—lymphatic system cancer	0.00066	0.00172	CcSEcCtD
Lercanidipine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000657	0.00171	CcSEcCtD
Lercanidipine—Chest pain—Carmustine—lymphatic system cancer	0.000656	0.00171	CcSEcCtD
Lercanidipine—Myalgia—Carmustine—lymphatic system cancer	0.000656	0.00171	CcSEcCtD
Lercanidipine—Anxiety—Carmustine—lymphatic system cancer	0.000654	0.0017	CcSEcCtD
Lercanidipine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000647	0.00168	CcSEcCtD
Lercanidipine—Malaise—Mitoxantrone—lymphatic system cancer	0.000646	0.00168	CcSEcCtD
Lercanidipine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000643	0.00167	CcSEcCtD
Lercanidipine—Confusional state—Carmustine—lymphatic system cancer	0.000634	0.00165	CcSEcCtD
Lercanidipine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000628	0.00164	CcSEcCtD
Lercanidipine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000627	0.00163	CcSEcCtD
Lercanidipine—Myalgia—Vincristine—lymphatic system cancer	0.000626	0.00163	CcSEcCtD
Lercanidipine—Cough—Mitoxantrone—lymphatic system cancer	0.000625	0.00163	CcSEcCtD
Lercanidipine—Vomiting—Fludarabine—lymphatic system cancer	0.000625	0.00163	CcSEcCtD
Lercanidipine—Rash—Fludarabine—lymphatic system cancer	0.00062	0.00161	CcSEcCtD
Lercanidipine—Dermatitis—Fludarabine—lymphatic system cancer	0.000619	0.00161	CcSEcCtD
Lercanidipine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000616	0.0016	CcSEcCtD
Lercanidipine—Headache—Fludarabine—lymphatic system cancer	0.000616	0.0016	CcSEcCtD
Lercanidipine—Tachycardia—Carmustine—lymphatic system cancer	0.000614	0.0016	CcSEcCtD
Lercanidipine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00061	0.00159	CcSEcCtD
Lercanidipine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00061	0.00159	CcSEcCtD
Lercanidipine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00061	0.00159	CcSEcCtD
Lercanidipine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000608	0.00158	CcSEcCtD
Lercanidipine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000605	0.00157	CcSEcCtD
Lercanidipine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000603	0.00157	CcSEcCtD
Lercanidipine—Anorexia—Carmustine—lymphatic system cancer	0.0006	0.00156	CcSEcCtD
Lercanidipine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000594	0.00155	CcSEcCtD
Lercanidipine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00059	0.00154	CcSEcCtD
Lercanidipine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000589	0.00153	CcSEcCtD
Lercanidipine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000588	0.00153	CcSEcCtD
Lercanidipine—Hypotension—Carmustine—lymphatic system cancer	0.000588	0.00153	CcSEcCtD
Lercanidipine—Nausea—Fludarabine—lymphatic system cancer	0.000584	0.00152	CcSEcCtD
Lercanidipine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000581	0.00151	CcSEcCtD
Lercanidipine—Shock—Mitoxantrone—lymphatic system cancer	0.000575	0.0015	CcSEcCtD
Lercanidipine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000573	0.00149	CcSEcCtD
Lercanidipine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000573	0.00149	CcSEcCtD
Lercanidipine—Urticaria—Bleomycin—lymphatic system cancer	0.000573	0.00149	CcSEcCtD
Lercanidipine—Anorexia—Vincristine—lymphatic system cancer	0.000572	0.00149	CcSEcCtD
Lercanidipine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000571	0.00149	CcSEcCtD
Lercanidipine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00057	0.00148	CcSEcCtD
Lercanidipine—Insomnia—Carmustine—lymphatic system cancer	0.000569	0.00148	CcSEcCtD
Lercanidipine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000568	0.00148	CcSEcCtD
Lercanidipine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000565	0.00147	CcSEcCtD
Lercanidipine—Paraesthesia—Carmustine—lymphatic system cancer	0.000565	0.00147	CcSEcCtD
Lercanidipine—Hypotension—Vincristine—lymphatic system cancer	0.000561	0.00146	CcSEcCtD
Lercanidipine—Dyspnoea—Carmustine—lymphatic system cancer	0.000561	0.00146	CcSEcCtD
Lercanidipine—Somnolence—Carmustine—lymphatic system cancer	0.000559	0.00146	CcSEcCtD
Lercanidipine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000557	0.00145	CcSEcCtD
Lercanidipine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000547	0.00142	CcSEcCtD
Lercanidipine—Decreased appetite—Carmustine—lymphatic system cancer	0.000547	0.00142	CcSEcCtD
Lercanidipine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000547	0.00142	CcSEcCtD
Lercanidipine—Insomnia—Vincristine—lymphatic system cancer	0.000543	0.00141	CcSEcCtD
Lercanidipine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000543	0.00141	CcSEcCtD
Lercanidipine—Paraesthesia—Vincristine—lymphatic system cancer	0.000539	0.0014	CcSEcCtD
Lercanidipine—Constipation—Carmustine—lymphatic system cancer	0.000538	0.0014	CcSEcCtD
Lercanidipine—Breast disorder—Methotrexate—lymphatic system cancer	0.000536	0.00139	CcSEcCtD
Lercanidipine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000534	0.00139	CcSEcCtD
Lercanidipine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000533	0.00139	CcSEcCtD
Lercanidipine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000531	0.00138	CcSEcCtD
Lercanidipine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000525	0.00137	CcSEcCtD
Lercanidipine—Decreased appetite—Vincristine—lymphatic system cancer	0.000522	0.00136	CcSEcCtD
Lercanidipine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000521	0.00136	CcSEcCtD
Lercanidipine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00052	0.00135	CcSEcCtD
Lercanidipine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000518	0.00135	CcSEcCtD
Lercanidipine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000518	0.00135	CcSEcCtD
Lercanidipine—Fatigue—Vincristine—lymphatic system cancer	0.000518	0.00135	CcSEcCtD
Lercanidipine—Asthenia—Bleomycin—lymphatic system cancer	0.000517	0.00135	CcSEcCtD
Lercanidipine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000515	0.00134	CcSEcCtD
Lercanidipine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000514	0.00134	CcSEcCtD
Lercanidipine—Constipation—Vincristine—lymphatic system cancer	0.000514	0.00134	CcSEcCtD
Lercanidipine—Asthma—Methotrexate—lymphatic system cancer	0.000512	0.00133	CcSEcCtD
Lercanidipine—Pruritus—Bleomycin—lymphatic system cancer	0.00051	0.00133	CcSEcCtD
Lercanidipine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000508	0.00132	CcSEcCtD
Lercanidipine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000504	0.00131	CcSEcCtD
Lercanidipine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000502	0.00131	CcSEcCtD
Lercanidipine—Constipation—Mitoxantrone—lymphatic system cancer	0.0005	0.0013	CcSEcCtD
Lercanidipine—Abdominal pain—Carmustine—lymphatic system cancer	0.000497	0.00129	CcSEcCtD
Lercanidipine—Body temperature increased—Carmustine—lymphatic system cancer	0.000497	0.00129	CcSEcCtD
Lercanidipine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000491	0.00128	CcSEcCtD
Lercanidipine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000487	0.00127	CcSEcCtD
Lercanidipine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000482	0.00125	CcSEcCtD
Lercanidipine—Neutropenia—Methotrexate—lymphatic system cancer	0.000479	0.00125	CcSEcCtD
Lercanidipine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000478	0.00124	CcSEcCtD
Lercanidipine—Abdominal pain—Vincristine—lymphatic system cancer	0.000475	0.00124	CcSEcCtD
Lercanidipine—Body temperature increased—Vincristine—lymphatic system cancer	0.000475	0.00124	CcSEcCtD
Lercanidipine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000472	0.00123	CcSEcCtD
Lercanidipine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000468	0.00122	CcSEcCtD
Lercanidipine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000465	0.00121	CcSEcCtD
Lercanidipine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000464	0.00121	CcSEcCtD
Lercanidipine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000462	0.0012	CcSEcCtD
Lercanidipine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000462	0.0012	CcSEcCtD
Lercanidipine—Vomiting—Bleomycin—lymphatic system cancer	0.000458	0.00119	CcSEcCtD
Lercanidipine—Rash—Bleomycin—lymphatic system cancer	0.000454	0.00118	CcSEcCtD
Lercanidipine—Dermatitis—Bleomycin—lymphatic system cancer	0.000454	0.00118	CcSEcCtD
Lercanidipine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000453	0.00118	CcSEcCtD
Lercanidipine—Asthenia—Carmustine—lymphatic system cancer	0.000451	0.00117	CcSEcCtD
Lercanidipine—Renal failure—Methotrexate—lymphatic system cancer	0.000449	0.00117	CcSEcCtD
Lercanidipine—Stomatitis—Methotrexate—lymphatic system cancer	0.000445	0.00116	CcSEcCtD
Lercanidipine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000442	0.00115	CcSEcCtD
Lercanidipine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000432	0.00112	CcSEcCtD
Lercanidipine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000431	0.00112	CcSEcCtD
Lercanidipine—Asthenia—Vincristine—lymphatic system cancer	0.000431	0.00112	CcSEcCtD
Lercanidipine—Diarrhoea—Carmustine—lymphatic system cancer	0.00043	0.00112	CcSEcCtD
Lercanidipine—Nausea—Bleomycin—lymphatic system cancer	0.000428	0.00111	CcSEcCtD
Lercanidipine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000426	0.00111	CcSEcCtD
Lercanidipine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00042	0.00109	CcSEcCtD
Lercanidipine—Dizziness—Carmustine—lymphatic system cancer	0.000416	0.00108	CcSEcCtD
Lercanidipine—Diarrhoea—Vincristine—lymphatic system cancer	0.000411	0.00107	CcSEcCtD
Lercanidipine—Hepatitis—Methotrexate—lymphatic system cancer	0.00041	0.00107	CcSEcCtD
Lercanidipine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000405	0.00105	CcSEcCtD
Lercanidipine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000402	0.00105	CcSEcCtD
Lercanidipine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0004	0.00104	CcSEcCtD
Lercanidipine—Vomiting—Carmustine—lymphatic system cancer	0.0004	0.00104	CcSEcCtD
Lercanidipine—Dizziness—Vincristine—lymphatic system cancer	0.000397	0.00103	CcSEcCtD
Lercanidipine—Rash—Carmustine—lymphatic system cancer	0.000397	0.00103	CcSEcCtD
Lercanidipine—Dermatitis—Carmustine—lymphatic system cancer	0.000396	0.00103	CcSEcCtD
Lercanidipine—Headache—Carmustine—lymphatic system cancer	0.000394	0.00103	CcSEcCtD
Lercanidipine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000388	0.00101	CcSEcCtD
Lercanidipine—Eye disorder—Methotrexate—lymphatic system cancer	0.000383	0.000998	CcSEcCtD
Lercanidipine—Tinnitus—Methotrexate—lymphatic system cancer	0.000382	0.000995	CcSEcCtD
Lercanidipine—Vomiting—Vincristine—lymphatic system cancer	0.000382	0.000994	CcSEcCtD
Lercanidipine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000381	0.000991	CcSEcCtD
Lercanidipine—Rash—Vincristine—lymphatic system cancer	0.000379	0.000986	CcSEcCtD
Lercanidipine—Dermatitis—Vincristine—lymphatic system cancer	0.000378	0.000985	CcSEcCtD
Lercanidipine—Headache—Vincristine—lymphatic system cancer	0.000376	0.000979	CcSEcCtD
Lercanidipine—Nausea—Carmustine—lymphatic system cancer	0.000374	0.000973	CcSEcCtD
Lercanidipine—Angiopathy—Methotrexate—lymphatic system cancer	0.000372	0.000969	CcSEcCtD
Lercanidipine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000372	0.000968	CcSEcCtD
Lercanidipine—Immune system disorder—Methotrexate—lymphatic system cancer	0.00037	0.000964	CcSEcCtD
Lercanidipine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00037	0.000962	CcSEcCtD
Lercanidipine—Rash—Mitoxantrone—lymphatic system cancer	0.000369	0.00096	CcSEcCtD
Lercanidipine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000368	0.000959	CcSEcCtD
Lercanidipine—Headache—Mitoxantrone—lymphatic system cancer	0.000366	0.000954	CcSEcCtD
Lercanidipine—Alopecia—Methotrexate—lymphatic system cancer	0.000362	0.000943	CcSEcCtD
Lercanidipine—Mental disorder—Methotrexate—lymphatic system cancer	0.000359	0.000935	CcSEcCtD
Lercanidipine—Erythema—Methotrexate—lymphatic system cancer	0.000357	0.000929	CcSEcCtD
Lercanidipine—Malnutrition—Methotrexate—lymphatic system cancer	0.000357	0.000929	CcSEcCtD
Lercanidipine—Nausea—Vincristine—lymphatic system cancer	0.000357	0.000929	CcSEcCtD
Lercanidipine—Dysgeusia—Methotrexate—lymphatic system cancer	0.00035	0.00091	CcSEcCtD
Lercanidipine—Nausea—Mitoxantrone—lymphatic system cancer	0.000347	0.000904	CcSEcCtD
Lercanidipine—Vision blurred—Methotrexate—lymphatic system cancer	0.000336	0.000876	CcSEcCtD
Lercanidipine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000331	0.000862	CcSEcCtD
Lercanidipine—Anaemia—Methotrexate—lymphatic system cancer	0.00033	0.000859	CcSEcCtD
Lercanidipine—Malaise—Methotrexate—lymphatic system cancer	0.000322	0.000838	CcSEcCtD
Lercanidipine—Vertigo—Methotrexate—lymphatic system cancer	0.000321	0.000835	CcSEcCtD
Lercanidipine—Cough—Methotrexate—lymphatic system cancer	0.000312	0.000811	CcSEcCtD
Lercanidipine—Arthralgia—Methotrexate—lymphatic system cancer	0.000304	0.000791	CcSEcCtD
Lercanidipine—Myalgia—Methotrexate—lymphatic system cancer	0.000304	0.000791	CcSEcCtD
Lercanidipine—Chest pain—Methotrexate—lymphatic system cancer	0.000304	0.000791	CcSEcCtD
Lercanidipine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000302	0.000786	CcSEcCtD
Lercanidipine—Discomfort—Methotrexate—lymphatic system cancer	0.0003	0.000782	CcSEcCtD
Lercanidipine—Confusional state—Methotrexate—lymphatic system cancer	0.000294	0.000765	CcSEcCtD
Lercanidipine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000286	0.000744	CcSEcCtD
Lercanidipine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000285	0.000743	CcSEcCtD
Lercanidipine—Skin disorder—Methotrexate—lymphatic system cancer	0.000283	0.000737	CcSEcCtD
Lercanidipine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000282	0.000733	CcSEcCtD
Lercanidipine—Anorexia—Methotrexate—lymphatic system cancer	0.000278	0.000723	CcSEcCtD
Lercanidipine—Hypotension—Methotrexate—lymphatic system cancer	0.000272	0.000709	CcSEcCtD
Lercanidipine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000265	0.000691	CcSEcCtD
Lercanidipine—Insomnia—Methotrexate—lymphatic system cancer	0.000264	0.000686	CcSEcCtD
Lercanidipine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000262	0.000681	CcSEcCtD
Lercanidipine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00026	0.000676	CcSEcCtD
Lercanidipine—Somnolence—Methotrexate—lymphatic system cancer	0.000259	0.000674	CcSEcCtD
Lercanidipine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000257	0.000668	CcSEcCtD
Lercanidipine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000253	0.000659	CcSEcCtD
Lercanidipine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000252	0.000655	CcSEcCtD
Lercanidipine—Fatigue—Methotrexate—lymphatic system cancer	0.000251	0.000654	CcSEcCtD
Lercanidipine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00024	0.000625	CcSEcCtD
Lercanidipine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000238	0.00062	CcSEcCtD
Lercanidipine—Urticaria—Methotrexate—lymphatic system cancer	0.000231	0.000603	CcSEcCtD
Lercanidipine—Abdominal pain—Methotrexate—lymphatic system cancer	0.00023	0.0006	CcSEcCtD
Lercanidipine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00023	0.0006	CcSEcCtD
Lercanidipine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000215	0.000559	CcSEcCtD
Lercanidipine—Asthenia—Methotrexate—lymphatic system cancer	0.000209	0.000544	CcSEcCtD
Lercanidipine—Pruritus—Methotrexate—lymphatic system cancer	0.000206	0.000537	CcSEcCtD
Lercanidipine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000199	0.000519	CcSEcCtD
Lercanidipine—Dizziness—Methotrexate—lymphatic system cancer	0.000193	0.000502	CcSEcCtD
Lercanidipine—Vomiting—Methotrexate—lymphatic system cancer	0.000185	0.000482	CcSEcCtD
Lercanidipine—Rash—Methotrexate—lymphatic system cancer	0.000184	0.000478	CcSEcCtD
Lercanidipine—Dermatitis—Methotrexate—lymphatic system cancer	0.000184	0.000478	CcSEcCtD
Lercanidipine—Headache—Methotrexate—lymphatic system cancer	0.000183	0.000475	CcSEcCtD
Lercanidipine—Nausea—Methotrexate—lymphatic system cancer	0.000173	0.000451	CcSEcCtD
